Zacks.com on MSN14h
Novartis' Gene Therapy Meets Primary Endpoint in SMA Study
Novartis NVS announced positive top-line results from the late-stage STEER study on experimental candidate intrathecal ...
Hosted on MSN18h
Novartis’ Phase III spinal muscular atrophy therapy trial meets primary endpoint
Novartis has reported positive topline outcomes from the Phase III STEER trial of an investigational gene therapy, ...
precisionmedicineonline17h
Novartis Reports Positive Data for Zolgensma in Young Adult Spinal Muscular Atrophy Population
The firm said it plans to share data with regulatory agencies from the Phase III STEER trial after it met its primary endpoint.